Login to Your Account



Financings NEWS

DUBLIN – Asit Biotech SA put a little color into Europe's anemic IPO market, raising €23.5 million (US$26.5 million) on the Euronext Exchange in Brussels and Paris last week.

DUBLIN – Novimmune SA closed a CHF30 million (US$31 million) funding round, taking the total cash it has raised this year to CHF60 million and its lifetime total to more than CHF300 million.

Things may soon be looking up for liposomal anthracycline L-annamycin, in the works for AML, if Moleculin Biotech Inc. has anything to say about it.

More Financings Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: